ATE556721T1 - Verbindungen zur intrazellurären abgabe von therapeutischen einheiten an nervenzellen - Google Patents
Verbindungen zur intrazellurären abgabe von therapeutischen einheiten an nervenzellenInfo
- Publication number
- ATE556721T1 ATE556721T1 AT99960608T AT99960608T ATE556721T1 AT E556721 T1 ATE556721 T1 AT E556721T1 AT 99960608 T AT99960608 T AT 99960608T AT 99960608 T AT99960608 T AT 99960608T AT E556721 T1 ATE556721 T1 AT E556721T1
- Authority
- AT
- Austria
- Prior art keywords
- intracellurary
- delivery
- compounds
- nerve cells
- compound
- Prior art date
Links
- 210000002569 neuron Anatomy 0.000 title abstract 5
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 230000001225 therapeutic effect Effects 0.000 title abstract 4
- 231100000065 noncytotoxic Toxicity 0.000 abstract 2
- 230000002020 noncytotoxic effect Effects 0.000 abstract 2
- 108010001857 Cell Surface Receptors Proteins 0.000 abstract 1
- 238000010521 absorption reaction Methods 0.000 abstract 1
- 239000011230 binding agent Substances 0.000 abstract 1
- 230000008878 coupling Effects 0.000 abstract 1
- 238000010168 coupling process Methods 0.000 abstract 1
- 238000005859 coupling reaction Methods 0.000 abstract 1
- 102000006240 membrane receptors Human genes 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/21—Hydrocarbon
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Psychiatry (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Virology (AREA)
- Pain & Pain Management (AREA)
- Communicable Diseases (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/217,037 US6652864B1 (en) | 1998-12-21 | 1998-12-21 | Compounds for intracellular delivery of therapeutic moieties to nerve cells |
| PCT/US1999/028211 WO2000037103A2 (en) | 1998-12-21 | 1999-11-29 | Compounds for intracellular delivery of therapeutic moieties to nerve cells |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE556721T1 true ATE556721T1 (de) | 2012-05-15 |
Family
ID=22809430
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT99960608T ATE556721T1 (de) | 1998-12-21 | 1999-11-29 | Verbindungen zur intrazellurären abgabe von therapeutischen einheiten an nervenzellen |
Country Status (7)
| Country | Link |
|---|---|
| US (5) | US6652864B1 (de) |
| EP (1) | EP1140201B1 (de) |
| JP (1) | JP2002532560A (de) |
| AT (1) | ATE556721T1 (de) |
| AU (1) | AU777207B2 (de) |
| CA (1) | CA2356454A1 (de) |
| WO (1) | WO2000037103A2 (de) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040120891A1 (en) | 1998-12-21 | 2004-06-24 | Craig Hill | Compounds for intracellular delivery of therapeutic moieties to nerve cells |
| US6652864B1 (en) | 1998-12-21 | 2003-11-25 | Asilomar Pharmaceuticals, Inc. | Compounds for intracellular delivery of therapeutic moieties to nerve cells |
| US6716452B1 (en) | 2000-08-22 | 2004-04-06 | New River Pharmaceuticals Inc. | Active agent delivery systems and methods for protecting and administering active agents |
| US7060708B2 (en) | 1999-03-10 | 2006-06-13 | New River Pharmaceuticals Inc. | Active agent delivery systems and methods for protecting and administering active agents |
| WO2003020200A2 (en) | 2000-11-16 | 2003-03-13 | New River Pharmaceuticals Inc. | A novel pharmaceutical compound and methods of making and using same |
| US20060280724A1 (en) * | 2000-11-04 | 2006-12-14 | Ferguson Ian A | Identification of ligands that enable endocytosis, using in vivo manipulation of neuronal fibers |
| WO2002047730A2 (en) * | 2000-11-06 | 2002-06-20 | Asilomar Pharmaceuticals, Inc | Intracellular delivery of charged therapeutic moieties to nerve cells by means of targeting proteins |
| ES2373641T3 (es) * | 2000-11-16 | 2012-02-07 | Shire Llc | Un nuevo compuesto farmacéutico y métodos para fabricarlo y usarlo. |
| AU2002216864A1 (en) * | 2000-12-21 | 2002-07-01 | Mcgill University | Conjugates of antibodies and anticancer drugs |
| US7375082B2 (en) | 2002-02-22 | 2008-05-20 | Shire Llc | Abuse-resistant hydrocodone compounds |
| US7338939B2 (en) | 2003-09-30 | 2008-03-04 | New River Pharmaceuticals Inc. | Abuse-resistant hydrocodone compounds |
| US7169752B2 (en) | 2003-09-30 | 2007-01-30 | New River Pharmaceuticals Inc. | Compounds and compositions for prevention of overdose of oxycodone |
| US20030158254A1 (en) * | 2002-01-24 | 2003-08-21 | Xenoport, Inc. | Engineering absorption of therapeutic compounds via colonic transporters |
| AU2003219863C1 (en) | 2002-02-22 | 2009-03-05 | Shire Llc | Novel sustained release pharmaceutical compounds to prevent abuse of controlled substances |
| UA80447C2 (en) | 2002-10-08 | 2007-09-25 | Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic | |
| US7569364B2 (en) * | 2002-12-24 | 2009-08-04 | Pfizer Inc. | Anti-NGF antibodies and methods using same |
| US9498530B2 (en) | 2002-12-24 | 2016-11-22 | Rinat Neuroscience Corp. | Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same |
| KR101250818B1 (ko) | 2002-12-24 | 2013-04-15 | 리나트 뉴로사이언스 코프. | 항-ｎｇｆ 항체 및 그것을 이용하는 방법 |
| JP4691500B2 (ja) | 2003-09-30 | 2011-06-01 | シャイア エルエルシー | 過剰摂取又は乱用を防止するための薬学組成物 |
| ITRM20030601A1 (it) | 2003-12-24 | 2005-06-25 | Lay Line Genomics Spa | Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti. |
| WO2006070290A2 (en) * | 2004-06-23 | 2006-07-06 | Ferguson Ian A | Agents and methods for early diagnosis and monitoring of alzheimer's disease and other neurological disorders |
| ITRM20050290A1 (it) | 2005-06-07 | 2006-12-08 | Lay Line Genomics Spa | Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato. |
| US7662177B2 (en) | 2006-04-12 | 2010-02-16 | Bacoustics, Llc | Apparatus and methods for pain relief using ultrasound waves in combination with cryogenic energy |
| EP2125024B1 (de) * | 2007-03-23 | 2013-02-13 | TO-BBB Holding B.V. | Gezielte intrazelluläre abgabe von antiviralen mitteln |
| JP6190723B2 (ja) | 2010-12-01 | 2017-08-30 | アルダーバイオ ホールディングス エルエルシー | 抗ｎｇｆ組成物およびその使用 |
| US9539324B2 (en) | 2010-12-01 | 2017-01-10 | Alderbio Holdings, Llc | Methods of preventing inflammation and treating pain using anti-NGF compositions |
| US9884909B2 (en) | 2010-12-01 | 2018-02-06 | Alderbio Holdings Llc | Anti-NGF compositions and use thereof |
| US9067988B2 (en) | 2010-12-01 | 2015-06-30 | Alderbio Holdings Llc | Methods of preventing or treating pain using anti-NGF antibodies |
| US11214610B2 (en) | 2010-12-01 | 2022-01-04 | H. Lundbeck A/S | High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris |
| US9078878B2 (en) | 2010-12-01 | 2015-07-14 | Alderbio Holdings Llc | Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75 |
| JP2021530507A (ja) * | 2018-07-18 | 2021-11-11 | マンザニータ ファーマシューティカルズ，インク． | 神経細胞に抗がん剤を送達するためのコンジュゲート、その使用方法及び製造方法 |
| EP4048736A4 (de) * | 2019-10-23 | 2023-11-01 | Manzanita Pharmaceuticals, Inc. | Neurotrophin-rezeptor-bindende konjugat-zusammensetzungen, verfahren zur verwendung und verfahren zum herstellen davon |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US554498A (en) * | 1896-02-11 | Bottle | ||
| US5087618A (en) | 1982-05-18 | 1992-02-11 | University Of Florida | Redox carriers for brain-specific drug delivery |
| US5563250A (en) | 1987-12-02 | 1996-10-08 | Neorx Corporation | Cleavable conjugates for the delivery and release of agents in native form |
| US5232695A (en) * | 1987-12-23 | 1993-08-03 | G. D. Searle & Co. | Method of ameliorating herpes simplex virus infections using purified nerve growth factor |
| US5486599A (en) * | 1989-03-29 | 1996-01-23 | The Board Of Trustees Of The Leland Stanford Junior University | Construction and use of synthetic constructs encoding syndecan |
| US5094848A (en) * | 1989-06-30 | 1992-03-10 | Neorx Corporation | Cleavable diphosphate and amidated diphosphate linkers |
| US5977307A (en) | 1989-09-07 | 1999-11-02 | Alkermes, Inc. | Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins |
| US5527527A (en) | 1989-09-07 | 1996-06-18 | Alkermes, Inc. | Transferrin receptor specific antibody-neuropharmaceutical agent conjugates |
| KR100236375B1 (ko) | 1989-12-11 | 1999-12-15 | 오트리브 데이비스 더블유 | 진단제 또는 치료제를 목표부위에 타게팅하기 위한 제제 및 키트 |
| US5948384A (en) | 1990-09-14 | 1999-09-07 | Syngenix Limited | Particulate agents |
| JPH06504274A (ja) | 1991-01-07 | 1994-05-19 | シンジェニックス・リミテッド | 微細粒子 |
| JP3542592B2 (ja) | 1991-08-30 | 2004-07-14 | シンジェニックス・リミテッド | 核酸ポリメラーゼ増幅 |
| DE69228127T2 (de) | 1991-11-15 | 1999-09-02 | Univ California | Therapie des zentralnervensystems mit genetisch modifizierten zellen |
| US5505931A (en) | 1993-03-04 | 1996-04-09 | The Dow Chemical Company | Acid cleavable compounds, their preparation and use as bifunctional acid-labile crosslinking agents |
| EP0599303A3 (de) * | 1992-11-27 | 1998-07-29 | Takeda Chemical Industries, Ltd. | Peptide-Konjugate |
| US5614487A (en) * | 1993-05-28 | 1997-03-25 | Genentech, Inc. | Sustained release pharmaceutical composition |
| US5502037A (en) | 1993-07-09 | 1996-03-26 | Neuromed Technologies, Inc. | Pro-cytotoxic drug conjugates for anticancer therapy |
| WO1995007092A1 (en) | 1993-09-10 | 1995-03-16 | The University Of Medicine And Dentistry Of New Jersey | Blood-brain barrier transporters of neurological agents |
| WO1995032738A1 (en) | 1994-05-31 | 1995-12-07 | Allergan, Inc. | Modification of clostridial toxins for use as transport proteins |
| US5728803A (en) * | 1994-06-03 | 1998-03-17 | Genentech, Inc. | Pantropic neurotrophic factors |
| US7144983B1 (en) * | 1997-02-03 | 2006-12-05 | Genentech, Inc. | Pantropic neurotrophic factors |
| GB9508204D0 (en) * | 1995-04-21 | 1995-06-07 | Speywood Lab Ltd | A novel agent able to modify peripheral afferent function |
| US5990078A (en) | 1995-07-14 | 1999-11-23 | The Trustees Of Columbia University In The City Of New York | Means of increasing estrogen receptor levels in neural tissue |
| US6267955B1 (en) | 1995-09-15 | 2001-07-31 | Yeda Research And Development Co. Ltd. | Mononuclear phagocytes and their use to promote axonal regeneration |
| GB9525180D0 (en) * | 1995-12-08 | 1996-02-07 | Univ Mcgill | Design of hormone-like antibodies with agonistic and antagonistic fuctions |
| WO1997023608A1 (en) | 1995-12-22 | 1997-07-03 | Chiron Corporation | Compositions and methods for targeting gene delivery vehicles using covalently bound targeting elements |
| US5767288A (en) | 1996-01-05 | 1998-06-16 | California Institute Of Technology | Photolabile linkers and probes |
| US6406710B1 (en) * | 1996-01-16 | 2002-06-18 | Nikos Panayotatos | Protein occlusion for delivery of small molecules |
| AU2242897A (en) * | 1996-01-16 | 1997-08-11 | Nikos Panayotatos | Protein occlusion for delivery of small molecules |
| US5994317A (en) | 1996-04-09 | 1999-11-30 | Vical Incorporated | Quaternary cytofectins |
| US5795909A (en) | 1996-05-22 | 1998-08-18 | Neuromedica, Inc. | DHA-pharmaceutical agent conjugates of taxanes |
| US6576636B2 (en) * | 1996-05-22 | 2003-06-10 | Protarga, Inc. | Method of treating a liver disorder with fatty acid-antiviral agent conjugates |
| US6197743B1 (en) * | 1996-07-26 | 2001-03-06 | The Trustees Of Boston University | Compositions and methods for the treatment of viral disorders |
| US5968921A (en) | 1997-10-24 | 1999-10-19 | Orgegon Health Sciences University | Compositions and methods for promoting nerve regeneration |
| US6486303B1 (en) * | 1998-04-14 | 2002-11-26 | University Of Medicine & Dentistry Of New Jersey | Method for making hormone heterodimers |
| US6652864B1 (en) | 1998-12-21 | 2003-11-25 | Asilomar Pharmaceuticals, Inc. | Compounds for intracellular delivery of therapeutic moieties to nerve cells |
| JP2003530299A (ja) | 1999-03-08 | 2003-10-14 | ゲルハルト グラウプナー， | 標的化薬物送達のための方法および組成物 |
| EP1286700A2 (de) | 2000-06-01 | 2003-03-05 | Universite Catholique De Louvain | Krebs aktivierte prodrugverbindungen |
-
1998
- 1998-12-21 US US09/217,037 patent/US6652864B1/en not_active Expired - Lifetime
-
1999
- 1999-11-29 WO PCT/US1999/028211 patent/WO2000037103A2/en active IP Right Grant
- 1999-11-29 AU AU17468/00A patent/AU777207B2/en not_active Ceased
- 1999-11-29 JP JP2000589213A patent/JP2002532560A/ja active Pending
- 1999-11-29 EP EP99960608A patent/EP1140201B1/de not_active Expired - Lifetime
- 1999-11-29 AT AT99960608T patent/ATE556721T1/de active
- 1999-11-29 CA CA002356454A patent/CA2356454A1/en not_active Abandoned
-
2000
- 2000-11-06 US US09/707,730 patent/US6887861B1/en not_active Expired - Lifetime
-
2003
- 2003-08-28 US US10/652,723 patent/US7678378B2/en not_active Expired - Fee Related
-
2008
- 2008-05-07 US US12/116,886 patent/US7718605B2/en not_active Expired - Fee Related
-
2010
- 2010-03-29 US US12/749,339 patent/US8138155B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US6887861B1 (en) | 2005-05-03 |
| CA2356454A1 (en) | 2000-06-29 |
| JP2002532560A (ja) | 2002-10-02 |
| US8138155B2 (en) | 2012-03-20 |
| EP1140201B1 (de) | 2012-05-09 |
| US7678378B2 (en) | 2010-03-16 |
| WO2000037103A3 (en) | 2000-10-19 |
| US20100266492A1 (en) | 2010-10-21 |
| US6652864B1 (en) | 2003-11-25 |
| EP1140201A2 (de) | 2001-10-10 |
| AU777207B2 (en) | 2004-10-07 |
| US20050260211A1 (en) | 2005-11-24 |
| WO2000037103A2 (en) | 2000-06-29 |
| US7718605B2 (en) | 2010-05-18 |
| AU1746800A (en) | 2000-07-12 |
| US20090124547A1 (en) | 2009-05-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE556721T1 (de) | Verbindungen zur intrazellurären abgabe von therapeutischen einheiten an nervenzellen | |
| TR200102800T2 (tr) | Yeni bileşikler. | |
| BR0107246A (pt) | Agentes diazabicìclicos ativos no sistema nervoso central | |
| GB9915437D0 (en) | Chemical compounds III | |
| TR200200986T2 (tr) | C-aril glukozid SGLT2 önleyicileri. | |
| TR200200912T2 (tr) | APRIL (çoğalma uyarıcı ligand) reseptörü (BCMA) ve kullanımları | |
| WO2002013833A3 (en) | SMALL MOLECULE INHIBITORS TARGETED AT Bcl-2 | |
| CO5251404A1 (es) | Compuestos antibioticos de azalida | |
| PT879820E (pt) | Analogos de benzamida, uteis como inibidores de enzima de reparacao de adn (adp-ribosil-transferase, adprt) | |
| BR0011856A (pt) | Agonistas de receptor a2a de n-pirazol | |
| SI1297013T1 (sl) | Uporaba TACI kot protitumorskega sredstva | |
| NO20052989L (no) | Terapeutiske forbindelser. | |
| BR0007864A (pt) | Composto, e, uso de um composto | |
| ES2172937T3 (es) | 21-hidroxi-6,19-oxidoprogesterona(21oh-6op) como medicamento para tratar el exceso de glucocorticoides. | |
| MY137143A (en) | Disposable diaper | |
| BG103558A (en) | Sulphonic acid or sulphonylamino n-(heteroaralkyl)-azaheterocyclylamide compounds | |
| TW261615B (de) | ||
| AU3012701A (en) | Use of methylchinolinium compounds for dyeing keratin containing fibers | |
| YU59400A (sh) | Azabiciklični ligandi 5ht1 receptora | |
| MX2007003105A (es) | Derivados de bencimidazol, composiciones que los contienen, sus preparaciones y sus usos i. | |
| AR029795A1 (es) | Derivados de acido 1,2,3,4-tetrahidroquinolin-2-carboxilico sustituidos, procedimientos para su preparacion, su uso para la preparacion de medicamentos y medicamentos que contienen estos compuestos | |
| MX9700245A (es) | Nuevo compuesto quimico, su preparacion y su empleo como medicamento. | |
| MY139676A (en) | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof | |
| AU2001267687A1 (en) | Ruthenium (ii) compounds for use in the therapy of cancer | |
| BRPI0415034A (pt) | derivados de aminopiridina como inibidores de não-sintase induzìveis |